The Medical Developments International Ltd (ASX: MVP) share price is down 2% to $5.04 in afternoon trade after the healthcare company released its full-year results.
Here are the key takeaways:
- Gross revenue from ordinary activities up 22% to $18.9 million.
- Profit after tax from operating activities up 16% to $1.82 million.
- Basic earnings per share of 3.1 cents.
- Final dividend of 2 cents per share fully franked, bringing its full-year dividend to 4 cents per share.
Medical Developments International is the company behind the Penthrox pain management product which is better known as the "green whistle".
A key driver in the company's revenue growth this year has been the global expansion of the product. Penthrox is available in 14 countries now.
But this is expected to grow significantly in the future.
According to today's release, the company is targeting new market approvals in 22 European countries over the next 6 months and 37 new countries in total over the next 12 months
